References
- Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1397–1407.
- (CDER) USDoHaHSFaDACfDEaR. Guidance for industry: irritable bowel syndrome – clinical evaluation of drugs for treatment. In: (CDER) USDoHaHSFaDACfDEaR, ed. Silver Spring, MD: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration; 2012. p. 1–14.
- Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–2234.
- Whitehead WE, Palsson OS, Simren M. Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterol Motil. 2016;28:783–792.
- Palsson OSW, Van Tilburg WE, Chang MAL, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenteology. 2016;150:1481–1491.
- Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol. 2010;105:814-20;quiz 813, 821.
- Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? Jama. 2008;300:1793–1805.
- Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol. 2014;109:1450–1460.
- Sood R, Gracie DJ, Law GR, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42:491–503.